MaxCyte MXCT Business Segments — Non Core Revenue

Similar metrics at other companies

DNACell Engineering — Revenue from Contract with Customer, Excluding Assessed Tax, Noncash

$500K-94.3%

MRAMEngineering services and other revenue — Total Revenue

$631K-57.0%

ACNTCore Technology — Net Sales

$4.11M-5.9%

VICRNon Recurring Engineering — Revenue

$1.59M-15.0%

CCOINon Core Services — Revenue (Gross)

$1.01M-66.6%

OPTXNon Recurring Engineering — Revenue

$28.88K-3.7%

Questions, answered.

What is MaxCyte's business segments — non core revenue?

MaxCyte (MXCT) reported business segments — non core revenue of $3.43M in Q1 2026.

How has MaxCyte's business segments — non core revenue changed year-over-year?

MaxCyte's business segments — non core revenue increased by 59.9% year-over-year, from $2.15M to $3.43M.

What is the long-term trend for MaxCyte's business segments — non core revenue?

Over 2 years (2023 to 2025), MaxCyte's business segments — non core revenue has grown at a -45.4% compound annual growth rate (CAGR), from $11.47M to $3.42M.

What does business segments — non core revenue mean?

Captures revenue streams derived from secondary or ancillary activities outside of the primary cell engineering platform sales and licensing. Monitoring this helps distinguish between sustainable core business growth and opportunistic or one-time revenue sources.